BusinessAdamas Announces Final Results from the Two-Year Phase 3 Open-Label Study of GOCOVRI™ in Parkinson’s Disease Patients with DyskinesiaBy Nasdaq OMXApr 19, 2018, 9:30 AM UTC
BusinessAdamas Announces Multiple Data Presentations at the American Academy of Neurology Annual MeetingBy Nasdaq OMXApr 12, 2018, 9:09 PM UTC
BusinessAdamas Announces Publication of Data Supporting the Benefits of GOCOVRI™ in Parkinson’s Disease Patients with DyskinesiaBy Nasdaq OMXMar 15, 2018, 1:01 PM UTC
BusinessAdamas Reports Recent Achievements and Financial Results for the Fourth Quarter and Full-Year 2017By Nasdaq OMXFeb 22, 2018, 9:01 PM UTC
BusinessAdamas Announces U.S. Commercial Launch of GOCOVRI™ the First and Only FDA-approved Medication for the Treatment of Dyskinesia in Parkinson’s Disease PatientsBy Nasdaq OMXJan 8, 2018, 9:41 PM UTC
BusinessAdamas Reports Recent Achievements and Third Quarter 2017 Financial ResultsBy Nasdaq OMXNov 2, 2017, 8:02 PM UTC
